Fidelity Disruptive Medicine ETF
FMED
12 hedge funds and large institutions have $42.8M invested in Fidelity Disruptive Medicine ETF in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
71% more funds holding
Funds holding: 7 → 12 (+5)
16% more capital invested
Capital invested by funds: $37M → $42.8M (+$5.75M)
1.6% more ownership
Funds ownership: 66.59% → 68.19% (+1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.2M |
| 2 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$852K |
| 3 |
BW
BXM Wealth
Englewood,
Colorado
|
+$242K |
| 4 |
VT
Vise Technologies
New York
|
+$233K |
| 5 |
VF
Virtu Financial
New York
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14.5K |
FMED Hedge Fund Activity: Q4 2025 in Review
12 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in Fidelity Disruptive Medicine ETF (FMED) for Q4 2025, worth a combined $42.8M — up 16% from $37M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new FMED positions and 0 closed out — a net gain of 5 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, adding an estimated $1.2M. The largest seller was UBS Group, cutting an estimated $14.5K.
- 12 institutional investors held Fidelity Disruptive Medicine ETF (FMED) as of Q4 2025, up from 7 in Q3 2025.
- Funds reported $42.8M of Fidelity Disruptive Medicine ETF stock for Q4 2025, up 16% quarter-over-quarter.
- 5 funds opened new Fidelity Disruptive Medicine ETF positions in Q4 2025 and 0 closed out, a net change of +5 holders.
- The largest Fidelity Disruptive Medicine ETF buyer in Q4 2025 was Jane Street, an estimated $1.2M added.
- The largest Fidelity Disruptive Medicine ETF seller in Q4 2025 was UBS Group, an estimated $14.5K sold.
Based on aggregated 13F filings for Q4 2025.